Aviragen Therapeutics (AVIR) Misses Q3 EPS by 11c

Aviragen Therapeutics (NASDAQ: AVIR) reported Q3 EPS of ($0.53), $0.11 worse than the analyst estimate of ($0.42).

For earnings history and earnings-related data on Aviragen Therapeutics (AVIR) click here.

You May Also Be Interested In

• Canaccord Starts BillionToOne Inc (BLLN) at Buy
• Needham Reiterates Buy Rating on Credo Tech (CRDO)
• GitLab Inc (GTLB) Tops Q2 EPS by 7c, Beats on Revenue